Table 3.

Associations of ovarian cancer with hormonal and reproductive factors by ADRB2

Age-adjusted modelaMultivariable modelb
ADRB2 statusADRB2 status
PositiveNegativePheterogeneityPositiveNegativePheterogeneity
N4519245192
Parity
Per child1.14 (0.98–1.34)0.90 (0.82–0.99)0.011.15 (0.98–1.34)0.91 (0.83–0.99)0.01
OC use
Per 5 years of use0.47 (0.23–0.99)0.98 (0.79–1.20)0.030.47 (0.23–0.99)0.97 (0.79–1.20)0.03
Breastfeeding
Per month1.00 (0.97–1.03)0.99 (0.97–1.00)0.380.99 (0.96–1.03)0.99 (0.97–1.01)0.80
Age at menarche
Per 1 year0.94 (0.77–1.16)1.04 (0.95–1.15)0.390.94 (0.76–1.16)1.05 (0.95–1.15)0.37
Age at menopausec
Per 1 year1.14 (1.02–1.27)1.00 (0.95–1.04)0.021.11 (1.00–1.24)0.99 (0.95–1.04)0.04
Lifetime ovulatory yearsd
Per 5 year1.63 (1.18–2.25)1.12 (0.98–1.29)0.031.60 (1.15–2.21)1.11 (0.96–1.27)0.04
Tubal ligation
No1.00 (ref)1.00 (ref)0.381.00 (ref)1.00 (ref)0.29
Yes0.50 (0.18–1.43)0.81 (0.53–1.22)0.49 (0.17–1.39)0.86 (0.57–1.31)
Hysterectomy
No1.00 (ref)1.00 (ref)0.931.00 (ref)1.00 (ref)0.83
Yes1.14 (0.56–2.33)1.19 (0.84–1.69)0.88 (0.42–1.84)0.96 (0.64–1.42)
Postmenopausal
No1.00 (ref)1.00 (ref)0.631.00 (ref)1.00 (ref)0.62
Yes1.42 (0.52–3.86)1.08 (0.66–1.79)1.47 (0.54–4.02)1.11 (0.67–1.83)
Estrogen HT use
Per 5 years of use1.27 (0.92–1.73)1.28 (1.10–1.49)0.941.22 (0.89–1.68)1.27 (1.09–1.48)0.83
Estrogen + progestin HT use
Per 5 years of use1.30 (0.76–2.25)1.19 (0.90–1.59)0.791.52 (0.87–2.67)1.23 (0.92–1.64)0.51
  • Abbreviations: HT, hormone therapy; OC, oral contraceptive.

  • aStratified by calendar year and cohort and adjusted for age.

  • bStratified by calendar year and cohort and adjusted for age, menopausal status, tubal ligation, duration of OC use, parity, and estrogen-only HT use.

  • cConducted among postmenopausal women.

  • dThe multivariable model for lifetime ovulatory years did not adjust for duration of OC use and parity.